LONDON, United Kingdom — An experimental daily cancer pill has delivered encouraging results in an early-stage trial involving patients with advanced pancreatic cancer, with some tumours shrinking significantly and others becoming undetectable on scans.
The drug, daraxonrasib, was tested alongside chemotherapy in 61 patients whose pancreatic cancer had spread to other parts of the body.
The findings offer fresh hope for a disease that remains among the hardest cancers to treat. However, researchers caution that the results do not establish a cure, and longer studies are needed to determine whether the treatment can extend patients’ lives.
What the trial found
The phase I/II study, known as RMC-GI-102, recorded the following results among the 61 participants:
- 90.2pc had disease control, meaning their tumours either shrank or did not progress.
- 60.7pc experienced tumour shrinkage or disappearance.
- 8.2pc had a complete response, with no detectable tumour on scans.
- Median progression-free survival was 12.8 months.
The patients had received daraxonrasib alongside two chemotherapy drugs, gemcitabine and nab-paclitaxel. The average follow-up period was 18.3 months.
The findings were presented at the 2026 EORTC-NCI-AACR Symposium in Barcelona, Spain, on November 20.
Dr Wungki Park, a gastrointestinal cancer specialist at Memorial Sloan Kettering Cancer Center and the study’s principal investigator, said the combination was producing deeper tumour responses and more sustained disease control than researchers had historically seen with chemotherapy alone.
However, the study was small and did not compare the combination against a separate group receiving chemotherapy alone. Its results therefore cannot yet establish how much the treatment improves survival compared with standard care.
How the pancreatic cancer pill works
Daraxonrasib is designed to block RAS proteins, which act as molecular switches involved in controlling cell growth.
More than 90pc of pancreatic cancers carry alterations in the RAS pathway, which can drive uncontrolled tumour growth. These proteins have historically been difficult to target with medicines, making the development of RAS inhibitors an important area of cancer research.
The drug is taken orally once a day. In the trial, it was combined with chemotherapy administered intravenously, rather than being used as a standalone pill treatment.
The United States Food and Drug Administration approved daraxonrasib, marketed as Rasonque, on August 26, 2026, for certain adults with metastatic pancreatic cancer who have received at least one previous systemic treatment, or who are not candidates for multi-drug systemic therapy.
That approval applies to a specific treatment setting. The combination with chemotherapy for patients receiving their first treatment for metastatic disease remains under investigation.
Larger trial needed to confirm the breakthrough
Researchers are now looking to a larger Phase III study, RASolute 303, to establish whether adding daraxonrasib to chemotherapy can improve outcomes for patients receiving their first treatment for metastatic pancreatic cancer.
The latest results also reported that 76.6pc of participants were alive 12 months after treatment began. While encouraging, this figure comes from the same small, non-randomised study and needs confirmation in larger trials.
Cancer experts have welcomed the findings but warn against interpreting the disappearance of tumours on scans as proof that the cancer has been eliminated permanently.

